Future study to address the efficacy of FGFR2 and CEBPB as neo-biomarkers for cancer risk stratification of CC patients and drug targets for bile duct cancer treatment in a larger patient cohort with long-term follow up is warranted. Here, CEBPB is linked to bile duct cancer.